Tesaro — Investor Presentation (January 2018)
47 slides from Tesaro's investor presentation, Jan 8, 2018
Slide 1: Safe Harbor Statement
Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S
Slide 2: TESARO: An Enduring Mission
TESARO: An Enduring Mission TESARO is a biopharmaceutical company devoted to providing transformative therapies to people bravely facing cancer. We see new possibilities to responsibly develop and commercialize innovative treatments where others may not. Relationships are vital to the success of our
Slide 3: 2017 Highlights
2017 Highlights OC: Ovarian cancer TNBC: Triple-negative breast cancer COMMERCIAL Four product launches: ZEJULA in U.S. and Europe, VARUBI IV in U.S., VARUBY in Europe ZEJULA added to NCCN Clinical Practice Guidelines in Oncology Ovarian Cancer version 1.2017 ZEJULA became the #1 prescribed PARPi in
Slide 4: Strong Financial and Strategic Position from which to Execute
Strong Financial and Strategic Position from which to Execute Two Commercial Products Portfolio Addresses Large Markets Balanced Product Pipeline Strong Financial Position ExperiencedTeam with U.S. and EU Reach CINV Ovarian Cancer Breast Cancer Lung Cancer Early to Late Stage I-O Approaches Small Mo
Slide 5: TESARO U.S. Commercial Execution
TESARO U.S. Commercial Execution Area Managers and Health Systems Managers (sales force) Medical Science Liaisons Oncology Nurse Educators Sales Leadership Key Customer Account Teams Sales Training Product Marketing ~170 Field-based Associates Field Management Full-scale Oncology Commercial & Medica
Slide 6: TESARO European Commercial Execution
TESARO European Commercial Execution Six offices to support product launches in 17 countries Team of 100 associates growing to 180 Niraparib Early Access Program has enrolled >570 patients to date ZEJULA and VARUBY launches underway Paris Madrid London Rome Zug Munich Initial European Commercial Org
Slide 7: Key Near-Term Value Drivers
Commercial Products: Solidify ZEJULA’s position as the market-leading PARP inhibitor in recurrent ovarian cancer in the US Execute on the ZEJULA launch in Europe Ovarian Franchise: Initiate a Phase 3 clinical trial of niraparib in combination with TSR-042 in first-line ovarian cancer in 1H 2018 Repo
Slide 8: More Time for More Women
More Time for More Women1 1ZEJULA increased progression-free survival (PFS) for women with recurrent ovarian cancer following complete or partial response to platinum-based chemotherapy in a randomized, placebo-controlled phase 3 trial. At the time of the PFS analysis, limited overall survival data
Slide 9: ZEJULA: The Only Once-Daily PARPi for Maintenance Treatment
3 FDA approved for patients with ovarian, fallopian tube, and peritoneal cancer in response to platinum based therapy. No biomarker test required ZEJULA®: The Only Once-Daily PARPi for Maintenance Treatment of Patients with Recurrent Ovarian Cancer 1 Highly selective PARP 1/2 inhibitor; once per day
Slide 10: NOVA Study Primary Endpoint PFS Results
NOVA Study Primary Endpoint PFS Results gBRCAmut Cohort Treatment PFS Median (95% CI) (Months) Hazard Ratio (95% CI) p-value % of Patients without Progression or Death 12 mo 18 mo Niraparib (N=234) 9.3 (7.2, 11.2) 0.45 (0.338, 0.607) p<0.0001 41% 30% Placebo (N=116) 3.9 (3.7, 5.5) 14% 12% PFS was an
Slide 11: The Market Leading PARPi
The Market Leading PARPi Source: TESARO data on file PAP: Patient Assistance Program Broad utilization of ZEJULA Treatment and maintenance settings Patients with and without BRCA mutations 25% to 30% of units shipped have been PAP or Quick Start Limited foundation support in ovarian cancer ~85% of p
Slide 12: U.S. Launch Off to a Strong Start
Total Patients Treated ~1,500 ~3,000* Total Prescribing Doctors >1,000 >1,700 BRCA status ~50% BRCAmut / ~50% non-BRCAmut ~50% BRCAmut / ~ 50% non-BRCAmut Reimbursement >95% of lives covered >99% of lives covered Refills Nearly 50% of units shipped in June ~70% of units shipped in September Gross to
Slide 13: Monthly PARPi Treated Patients with Ovarian Cancer
Monthly PARPi Treated Patients with Ovarian Cancer* ZEJULA Has Achieved Rapid Uptake and Leading Market Share Among All Ovarian Cancer Patients Note: Reflects both commercial and free product through patient assistance programs; Source: IntrinsiQ Data, © Copyright 2016, IntrinsiQ Specialty Solutions
Slide 14: Initial ZEJULA Utilization Primarily for Patients with Ovarian Cancer
Ovarian Breast Prostate Other ZEJULA Initial ZEJULA Utilization Primarily for Patients with Ovarian Cancer Olaparib Source: Specialty Pharmacy and Specialty Distributor data; IntrinsiQ Data, © Copyright 2016, IntrinsiQ Specialty Solutions, Inc. an AmerisourceBergen Specialty Group company. All right
Slide 15: PARPi Maintenance Share Among 2L & 3L Platinum Responders
PARPi Maintenance Share Among 2L & 3L Platinum Responders ~26%; ZEJULA Share of PARPi Class ~60% Source: TESARO ATU (awareness, trial, usage) Market Research Tracking Study. Maintenance Therapy – Patients Who Respond to Induction (PR or CR) 2L & 3L Platinum-sensitive Patients Watch and Wait has decr
Slide 16: Treatment Durations to Grow with Additional Maintenance Setting Use
Treatment Durations to Grow with Additional Maintenance Setting Use *Treatment / other patients expected to have durations of <6 months **Maintenance patient durations expected to grow from <9 months to >15 months 10,000 new patients/year or ~180 patients/ week eligible for maintenance Durations exp
Slide 17: Favorable ZEJULA Attributes In-line with Promotional Messaging
Favorable ZEJULA Attributes In-line with Promotional Messaging O Green circle: ZEJULA significantly outperforms competitor Thick circles indicate significant differences at 95% confidence, thin circles at 90% Note: Attributes listed in descending order of importance as per Baseline ATU Product Attri
Slide 18: Clinical Practice is Consistent with NOVA Results
Clinical Practice is Consistent with NOVA Results aThrombocytopenia=thrombocytopenia and decreased platelet count. No grade 3 or 4 bleeding events were associated with thrombocytopenia; banemia=anemia and decreased hemoglobin counts; cneutropenia=neutropenia, decreased neutrophil count, and febrile
Slide 19: ZEJULA Dose is Individualized for Each Patient by Cycle
ZEJULA Dose is Individualized for Each Patient by Cycle 3 for the Vast Majority of Patients Wang J, et al. Poster presentation at ESMO 2017. Abstract #933PD. 300 mg 200 mg 100 mg After Dose Modification, 200mg was the Most Commonly Administered Dose 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% 1 2 3
Slide 20: Dose Reductions Did Not Compromise Efficacy
BRCAmut BRCAwt Dose Reductions Did Not Compromise Efficacy BRCA = breast cancer susceptibility gene; BRCAmut = BRCA mutation; BRCAwt = BRCA wild-type; PFS = progression-free survival. 1. Based on exploratory analysis; Wang J, et al. Poster presentation at ESMO 2017. Abstract #933PD. 2. TESARO, Inc.
Slide 21: Three Strategic Imperatives to Maximize Value of ZEJULA in Ovarian Cancer
Three Strategic Imperatives to Maximize Value of ZEJULA® in Ovarian Cancer Establish Broad Leadership Position in First-line Treatment of OvCa Through Successful Registrations from PRIMA, and in Combination Use Strengthen Leadership Position in Recurrent Platinum-responsive Ovarian Cancer Advance St
Slide 22: Large Market Opportunities in Ovarian Cancer
Large Market Opportunities in Ovarian Cancer Source: Kantar Health, Data on file; Company estimates 1Assumes PARPi dosage forms that allow for flat pricing Solidify Leadership Position in Recurrent Ovarian Cancer Platinum Responsive (NOVA) Platinum Resistant (TOPACIO) Year 1 Incidence of U.S. & EU17
Slide 23: Large Development Opportunities Beyond Current Indication
Large Development Opportunities Beyond Current Indication Recurrent OC Maintenance (NOVA) 1L Maintenance (PRIMA, FIRST) Lung + TNBC Combinations IO Portfolio Combination Sales $4B $8B $1B
Slide 24: Establish Leadership in Front-Line with PRIMA
Endpoint assessment Niraparib 300 mg Daily Treatment Stratify on HRD CR or PR following platinum based chemotherapy Hierarchical Testing for PFS (radiologic, central review) PFS in HRDpos population (HR 0.5) PFS in ITT population (HR 0.65) Primary Endpoint Ovarian Cancer with high risk for progressi
Slide 25: AVANOVA: Niraparib + Bevacizumab
AVANOVA: Niraparib + Bevacizumab Phase 2, N=94 Stratify on HRD and PFI (>6-12 months or 12+ months) Phase 1, N = 12 Recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancer w/high-grade serous/endometrioid histology Objectives Phase 1: Safety and tolerability of
Slide 26: TOPACIO: Niraparib + anti-PD-1
TOPACIO: Niraparib + anti-PD-1 1 2014 SABC 2 J Clin Oncol 32:5s, 2014 (suppl; abstr 5511) 3 Rucaparib package insert; Gelmon, Lancet Oncol., 2011 Sep;12(9):852-61 N: niraparib; P: pembrolizumab Phase 1/2 TOPACIO Trial Niraparib + Pembrolizumab Objectives Phase 1: Establish Phase 2 dose Phase 2: Resp
Slide 27: Multiple Ongoing Studies in NSCLC Patients to Support a Phase 3 Study
Multiple Ongoing Monotherapy and Combination Studies in NSCLC Patients to Support a Phase 3 Study * Source: Kantar Health 1. Marquard et al , Postel-Vinay Nature Rev Clin Onc 9:144 2012; Postel-Vinay Oncogene 2013 1-11, Lee et al Clin Can Res 13:832; 2. Sandhu et al Lancet Onc 2013; a. Clin Cancer R
Slide 28: Advancing a Broad I-O Pipeline
Advancing a Broad I-O Pipeline Current Status Compound Indication Pre- clinical Ph 1 Ph 2 Ph 3 TSR-042 Anti-PD-1 mAb MSI-H tumors TSR-022 Anti-TIM-3 mAb Various tumor types TSR-033 Anti-LAG-3 mAb Various tumor types Anti-LAG-3/PD-1 dual reactive mAb Various tumor types Undisclosed small molecules Va
Slide 29: PD-1/L1 pathway blockade reinvigorates exhausted T cells
PD-1/L1 pathway blockade reinvigorates exhausted T cells following chronic viral infection Freeman et al, JEM 2006 Blocking the PD-1/L1 pathway can reverse exhausted T cells to expand and regain effector functions Blockade results in increase in cytokine production, cytolysis and reduction of viral
Slide 30: Exhausted T cells express high levels of PD-1
Exhausted T cells express high levels of PD-1 and PD-1 level is associated with increased viral load in HIV patients Palmer et al, 2013; Day et al, Nature 2006 PD-1 expression is increased on CD4+ and CD8+ T cells in HIV infected subjects PD-1 expression correlates with increased viral load Humanize
Slide 31: PD-1/L1 blockade reverses T cell exhaustion
PD-1/L1 pathway blockade reverses T cell exhaustion and increases proliferation of CD4+ and CD8+ T cells Palmer et al, 2013; Day et al 2006 Humanized in vivo model of HIV infection Th1 cytokines are elevated following anti-PD-L1 treatment CD8+IFN-γ+ cells (%) Control Anti-PD-L1 + anti-PD-L2 CD3+CD4+
Slide 32: Inhibition of PD-1/L1 pathway decreases viral load
Inhibition of PD-1/L1 pathway results in decreased viral load and increased CD4+ and CD8+ T cells in vivo Palmer et al, 2013 Inhibition of viral load Increase in CD4+ and CD8+ cells Humanized in vivo model of HIV infection
Slide 33: PD-1 blockade results in durable responses for cancer patients
PD-1 blockade results in durable responses for cancer patients Brahmer et al., ASCO 2017 KEYNOTE-024: Ph3 Pembrolizumab in 1L NSCLC, PD-L1 >50%
Slide 34: Reinvigoration of CD8+ T cells translates to better outcomes in NSCLC
Reinvigoration of CD8+ T cells translates to better outcomes in NSCLC patients Kamphorst et al. PNAS 2017 Proliferation of CD8+ T cells can be detected after anti-PD-1 therapy Early proliferation of PD-1+ CD8 T cells correlates with clinical outcome
Slide 35: TIM-3 and LAG-3: Reversible Exhausted T cell Phenotype
TIM-3 and LAG-3: Associated with induced Reversible Exhausted T cell Phenotype in Patients with Chronic Viral Infection Jones et al, JEM 2008; Tian et al, J Immunol 2015; Golden-Mason et al, 2009 LAG-3 TIM-3 Correlation with viral load Increased expression Blockade rescues exhausted T cell anti-TIM-
Slide 36: Greater T cell function with dual blockade of checkpoints
Greater T cell function is observed with dual blockade of checkpoints Wherry et al, Nature Immunology 2009 Dual PD-L1 + LAG3 blockade results in improved viral control LAG-3 + PD-L1 blockade improves function of exhausted CD8+ T cells
Slide 37: TSR-042 is a Strategic Asset for TESARO
Significant I-O/I-O Combination Value Targeted Development Opportunities Potential q6w Dosing TSR-042 is a Strategic Asset for TESARO MONTH 1 MONTH 2
Slide 38: GARNET: Phase Expansion Initiated to Support TSR-042 Registration
GARNET: Phase 1 Expansion Initiated to Support TSR-042 Registration *Expansion to be initiated after confirmation of PK and safety of the fixed doses. **Current accelerated approval opportunity. D. T. Le et al., Science 10.1126/science.aan6733 (2017). Endometrial Cancer (MSS) <1/3 DLT <1/3 DLT Other
Slide 39: Therapeutic Concept for TIM-3 Blockade
Therapeutic Concept for TIM-3 Blockade aTIM-3, in Combination with aPD-1, will Enhance Immune Cell Activation Resulting in Improved and Durable Anti-tumor Activity Improve Responses to aPD-1 TIM-3 upregulation post-PD(L)-1 blockade can contribute to adaptive immune resistance and tumor progression T
Slide 40: TIM-3: T cell immunoglobulin and mucin-domain containing-3
Monney et al. Nature 2002, Sabatos et. Al. Nature Immunol 2003, Sanchez-Fueyo et. Al. Nat Immunol 2003, Wherry et. Al. Nat Immunol 2011, Jin et. Al. PNAS 2010, Rahman et al.J Clin Cell Immunol 2012, Jones et. Al. J Exp Med 2008, Golden-Mason, J Virol 2009. TIM-3: T cell immunoglobulin and mucin-doma
Slide 41: AMBER: Dose Escalation of TSR-022 as Monotherapy and in Combination
AMBER: Phase 1 Dose Escalation of TSR-022 as Monotherapy and in Combination Setting DL1: 0.03mg/kg n=3+3 DL2: 0.1mg/kg n=3+3 <1/3 DLT DL3: 0.3mg/kg n=3+3 <1/3 DLT DL4: 1.0 mg/kg n=3+3 <1/3 DLT DL5: 3.0 mg/kg n=3+3 <1/3 DLT DL6: 10.0 mg/kg n=3+3 <1/3 DLT CDL1: TSR-022 + TSR-042 <1/3 DLT <1/3 DLT CDL2
Slide 42: LAG-3 is one of 3 Checkpoints Associated with Exhausted T-cells
Poly-functional memory cell Naïve CD8 T-cell PD-1 PD-1 TIM-3 PD-1 TIM-3 LAG-3 Elimination of antigen Persistent stimulation + inflammation IFNg TNFa IL-2 CTL IFNg TNFa CTL IFNg Progressive acquisition of checkpoints associated with reduced functionality IL-2 Proliferation Exhausted LAG-3 is one of 3
Slide 43: CITRINO: Phase 1 Evaluation of TSR-033 Dose Escalation
Part 1: DLT Based Dose Escalation and Combination with TSR-042 Part 2: Expansion Cohorts CITRINO: Phase 1 Evaluation of TSR-033 (Anti-LAG-3): Dose Escalation and Expansion into anti-PD-1 Combination 20 mg n= 3+3 240 mg n=6 80 mg n=6 <1/3 DLT <1/3 DLT 80 mg TSR-033 + TSR-042 n=3-6 240 mg TSR-033 + TS
Slide 44: CITRINO: Phase 1 Evaluation of TSR-033 (Anti-LAG-3)
CITRINO: Phase 1 Evaluation of TSR-033 (Anti-LAG-3): Dose Escalation and Expansion into anti-PD-1 Combination <1/3 DLT 20mg n= 343 <1/3DLT | 240mg 16 80mg n=6 240 mg TSR-033 —>| + TSR-042 n=3-6 80 mg TSR-033, + TSR-042 n=3-6 Endometrial Cancer «| 4PTESARO
Slide 45: VARUBI for Prevention of Delayed CINV
3 No dose adjustment for dexamethasone, a CYP3A4 substrate, and polysorbate-80 free (IV only) 1 Provides protection from CINV for the full delayed risk period (25-120 hours) 2 Oral and IV formulations available 4 Flexibility to use with any 5-HT3 receptor antagonist 5 Single dose administration just
Slide 46: January 2018 Investor Meetings
January 2018 Investor Meetings
Slide 47: TESARO January 2018 Investor Meetings
w TESARO January 2018 Investor Meetings